Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
m (Created page with "==General information== Class: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor<ref name="insert">[http://www.shire.com/shireplc/dlibrary/...") |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
Class: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor<ref name="insert">[http://www.shire.com/shireplc/dlibrary/documents/AgrylinUSPIAug2009.pdf Anagrelide (Agrylin) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/anagrelide.pdf Anagrelide (Agrylin) package insert (locally hosted backup)]</ref> | Class: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor<ref name="insert">[http://www.shire.com/shireplc/dlibrary/documents/AgrylinUSPIAug2009.pdf Anagrelide (Agrylin) package insert]</ref><ref>[http://hemonc.org/docs/chemotherapypackageinsert/anagrelide.pdf Anagrelide (Agrylin) package insert (locally hosted backup)]</ref> | ||
| − | <br>Extravasation: | + | <br>Route: PO |
| + | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
| Line 8: | Line 9: | ||
*[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/anagrelide-patient-drug-information Anagrelide (Agrylin) patient drug information (UpToDate)]</ref> | ||
| − | == | + | ==Regimen== |
| − | + | Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose) | |
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 22:23, 15 November 2011
General information
Class: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Patient drug information
Regimen
Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)